MX2023003129A - Compuestos trifenil-calciliticos para el tratamiento de hipocalcemia autosomica dominante tipo 1 (adh1). - Google Patents

Compuestos trifenil-calciliticos para el tratamiento de hipocalcemia autosomica dominante tipo 1 (adh1).

Info

Publication number
MX2023003129A
MX2023003129A MX2023003129A MX2023003129A MX2023003129A MX 2023003129 A MX2023003129 A MX 2023003129A MX 2023003129 A MX2023003129 A MX 2023003129A MX 2023003129 A MX2023003129 A MX 2023003129A MX 2023003129 A MX2023003129 A MX 2023003129A
Authority
MX
Mexico
Prior art keywords
adh1
type
autosomal dominant
triphenyl
treatment
Prior art date
Application number
MX2023003129A
Other languages
English (en)
Spanish (es)
Inventor
Ali Komeyli
Ananth Sridhar
Simon Bruce
Jonathan Fox
Ramei Sani-Grosso
Mary Scott Roberts
Michael T Collins
Rachel I Gafni
Kelly B L Roszko
Iris R Hartley
Karen A Pozo
Original Assignee
Calcilytix Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Calcilytix Therapeutics Inc filed Critical Calcilytix Therapeutics Inc
Publication of MX2023003129A publication Critical patent/MX2023003129A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MX2023003129A 2020-09-18 2021-09-16 Compuestos trifenil-calciliticos para el tratamiento de hipocalcemia autosomica dominante tipo 1 (adh1). MX2023003129A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063080165P 2020-09-18 2020-09-18
US202163159397P 2021-03-10 2021-03-10
PCT/US2021/050677 WO2022060987A1 (en) 2020-09-18 2021-09-16 Triphenyl calcilytic compounds for the treatment of autosomal dominant hypocalcemia type 1 (adh1)

Publications (1)

Publication Number Publication Date
MX2023003129A true MX2023003129A (es) 2023-08-04

Family

ID=78087574

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023003129A MX2023003129A (es) 2020-09-18 2021-09-16 Compuestos trifenil-calciliticos para el tratamiento de hipocalcemia autosomica dominante tipo 1 (adh1).

Country Status (10)

Country Link
US (1) US20220087961A1 (cg-RX-API-DMAC7.html)
EP (1) EP4213829A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023542932A (cg-RX-API-DMAC7.html)
KR (1) KR20230112609A (cg-RX-API-DMAC7.html)
AU (1) AU2021343475A1 (cg-RX-API-DMAC7.html)
CA (1) CA3192684A1 (cg-RX-API-DMAC7.html)
IL (1) IL301409A (cg-RX-API-DMAC7.html)
MX (1) MX2023003129A (cg-RX-API-DMAC7.html)
TW (1) TW202227046A (cg-RX-API-DMAC7.html)
WO (1) WO2022060987A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116648243A (zh) 2020-08-04 2023-08-25 柯西立提克斯疗法有限公司 三苯基钙敏感化合物的制剂
WO2024220796A1 (en) * 2023-04-21 2024-10-24 Calcilytix Therapeutics, Inc. Treatment of hypoparathyroidism using triphenyl calcilytic compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20050460A1 (es) * 2003-04-23 2005-07-08 Japan Tobacco Inc COMPUESTOS HETEROCICLICOS COMO ANTAGONISTAS CaSR (RECEPTOR SENSIBLE AL CALCIO)
CN116648243A (zh) * 2020-08-04 2023-08-25 柯西立提克斯疗法有限公司 三苯基钙敏感化合物的制剂

Also Published As

Publication number Publication date
EP4213829A1 (en) 2023-07-26
WO2022060987A1 (en) 2022-03-24
IL301409A (en) 2023-05-01
US20220087961A1 (en) 2022-03-24
AU2021343475A1 (en) 2023-06-01
TW202227046A (zh) 2022-07-16
KR20230112609A (ko) 2023-07-27
AU2021343475A9 (en) 2024-05-02
CA3192684A1 (en) 2022-03-24
JP2023542932A (ja) 2023-10-12

Similar Documents

Publication Publication Date Title
CR20250500A (es) Inhibidores de kras de 2-azabiciclo [2.2.1] heptano
MX2022003018A (es) Danavorexton (tak-925) para usarse en el tratamiento de la narcolepsia.
BR112015021982A2 (pt) compostos e seus usos para a modulação de hemoglobina
ES8700053A1 (es) Procedimiento de obtencion de una composicion para el trata-miento de infecciones virales
MX2022009967A (es) Compuestos para el tratamiento de la infeccion por coronavirus.
MX2023012840A (es) Derivados de ftalazinona como inhibidores del inflamasoma nlrp3.
MX2024011403A (es) Tratamiento con mirdametinib.
WO2023107574A3 (en) Lipid-based compositions and methods thereof
WO2023147297A3 (en) Combination therapy for treating abnormal cell growth
MX2025009374A (es) Compuesto que contiene trifluorometilsulfonilo
MX2023013972A (es) Compuesto de quinolinamina, metodo de preparacion y aplicacion del mismo en productos farmaceuticos.
MX2024012882A (es) Compuestos de liberacion de gamma-hidroxibutirato y procesos para fabricar y usar los mismos
PH12022552495A1 (en) Oxazolidinone compound and methods of use thereof as an antibacterial agent
MX2026001837A (es) Compuestos que contienen ciclobutilo
JOP20250057A1 (ar) مركبات لعلاج السرطان
MX2024013787A (es) Inhibidores de menina-mll para el tratamiento de cáncer.
MX2023009600A (es) Análogos de la oxa-ibogaína para el tratamiento de trastornos por consumo de sustancias.
MX2024010480A (es) Uso de inhibidor de captacion triple para el tratamiento de la depresion atipica.
Fleisher et al. 1, 1'-Trimethylene bis (4-formylpyridinium bromide) dioxime (TMB-4) and 2-pyridine aldoxime methiodide (2-PAM) as adjuvants to atropine in the treatment of anticholinesterase poisoning
WO2022081610A8 (en) TREATMENT OF COGNITIVE IMPAIRMENT WITH A CNS-PENETRANT sGC STIMULATOR
EA202290215A1 (ru) Соединения и способы их применения в качестве антибактериальных агентов
WO2024249254A3 (en) Methods of using apol1 inhibitors
MX2023004435A (es) Compuestos y composiciones para el tratamiento de la criptosporidiosis.
CR20230487A (es) Compuestos cíclicos y métodos de uso
KR880009950A (ko) 항진균성 2-아닐리노티아졸린